Insmed Incorporated (NASDAQ:INSM) COO Sells $100,125.04 in Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 1,457 shares of the firm’s stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $68.72, for a total value of $100,125.04. Following the transaction, the chief operating officer now owns 146,082 shares of the company’s stock, valued at approximately $10,038,755.04. This represents a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Roger Adsett also recently made the following trade(s):

• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The stock was sold at an average price of $63.68, for a total value of $312,159.36.
• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The stock was sold at an average price of $65.95, for a total value of $161,181.80.

Insmed Price Performance

Insmed stock opened at $72.51 on Friday. The company has a fifty day simple moving average of $71.18 and a 200-day simple moving average of $72.57. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $80.53. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock has a market cap of $12.97 billion, a P/E ratio of -13.06 and a beta of 1.12.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to analysts’ expectations of $93.36 million. During the same quarter in the prior year, the company earned ($1.10) EPS. Insmed’s quarterly revenue was up 18.1% compared to the same quarter last year. Equities analysts expect that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on INSM. Bank of America raised their price target on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. JPMorgan Chase & Co. lifted their target price on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a report on Friday, November 22nd. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Insmed in a report on Friday, November 1st. Finally, Truist Financial reiterated a “buy” rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $83.67.

Institutional Investors Weigh In On Insmed

Hedge funds and other institutional investors have recently bought and sold shares of the stock. V Square Quantitative Management LLC acquired a new stake in Insmed during the 3rd quarter worth $30,000. GAMMA Investing LLC raised its stake in Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 627 shares during the period. JCIC Asset Management Inc. acquired a new position in Insmed in the third quarter valued at $133,000. Finally, Quantbot Technologies LP acquired a new position in Insmed in the third quarter valued at $133,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.